Resverlogix (TSE:RVX) has released an update.
At the European Society of Cardiology Congress 2024, Resverlogix Corp. highlighted the cardioprotective benefits of its drug apabetalone, which, in conjunction with other treatments, showed a 63% reduction in major adverse cardiac events and heart failure in patients. The company’s data promoted the drug as a beneficial addition to current treatments for cardiovascular and metabolic diseases, with the potential to improve patient outcomes significantly.
For further insights into TSE:RVX stock, check out TipRanks’ Stock Analysis page.
